Indication: Multiple Myeloma
Open-label, Multicenter, Non-randomized Phase 2 Study OF PF-06863135 Monotherapy in PARTICIPANTS WITH Multiple Myeloma WHO ARE REFRACTORY TO At LEAST One PROTEASOME Inhibitor, ONE immunomodulatory drug and ONE anti-cd38
antibody
Sub-indication: Hematological Malignancies
Drug Study
Principal Investigator: Don Stevens, M.D.Norton Cancer Institute
Sponsor: Pfizer
